Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 5,570 matching trials from the live ClinicalTrials.gov search.
Conditions
Colorectal Cancer
Interventions
cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy
Dietary Supplement · Genetic · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Colonic Neoplasms, Colorectal Neoplasms
Interventions
GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Adjuvant chemotherapy
Drug
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Cincinnati, Ohio
Conditions
HIV
Interventions
Dolutegravir, Emtricitabine/Tenofovir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
STAT Inhibitor OPB-111077, Decitabine, Venetoclax, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Peritoneal (Metastatic) Cancer, Peritoneal Carcinomatosis, Abdominal Cancer, Abdominal Cancer Patients
Interventions
Heated intra-peritoneal chemotherapy, Aerosolized intra-peritoneal chemotherapy
Procedure
Lead sponsor
Patrick Wagner, MD, FACS
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
PEN-866 Sodium, fluorouracil, Folinic acid, Niraparib
Drug
Lead sponsor
Tarveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
16
States / cities
Springdale, Arkansas • Denver, Colorado • Fort Myers, Florida + 13 more
Conditions
Overactive Bladder (OAB)
Interventions
NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham
Combination Product
Lead sponsor
Vensica Therapeutics Ltd.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Margate, Florida • Pompano Beach, Florida • Reno, Nevada
Conditions
Opioid-related Disorders
Interventions
Buprenorphine soluble film, Buprenorphine/naloxone film strip, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Results available

AFQ056 for Language Learning in Children With FXS

NCT02920892
Conditions
Fragile X Syndrome
Interventions
AFQ056, Placebo, Language Intervention
Drug · Other
Lead sponsor
Elizabeth Berry-Kravis
Other
Eligibility
32 Months to 6 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
14
States / cities
Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Opioid Analgesic Reduction Study

NCT04452344
Conditions
Opioid Use
Interventions
opioid-containing analgesic, two over-the-counter analgesics
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Nelfinavir (Viracept®) 1250 mg, Chemoradiation
Drug · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions
AL3818, Nivolumab Injection
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Santa Monica, California
Completed Phase 4 Interventional Results available

Buprenorphine Loading in the Emergency Department

NCT04283500
Conditions
Opioid-use Disorder
Interventions
Buprenorphine Naloxone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
13 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
San Diego, California • San Francisco, California • Wilmington, Delaware + 15 more
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
AUY922, Bortezomib, Dexamethasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Conditions
Stutter, Stuttering, Adult, Stuttering, Stuttering, Developmental
Interventions
Speech Production During functional magnetic resonance imaging (MRI)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
Conditions
Tumors, Neoplasms, Cancer
Interventions
LB-100 for Injection, Docetaxel
Drug
Lead sponsor
Lixte Biotechnology Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Duarte, California • Rochester, Minnesota • Las Vegas, Nevada + 2 more
Conditions
Atopic Dermatitis
Interventions
Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab
Dietary Supplement · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more
Conditions
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
64
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Conditions
Hepatitis C, Awaiting Organ Transplant
Interventions
Sofosbuvir/velpatasvir, Monitoring
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions
JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration
Procedure · Radiation · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Duarte, California • Irvine, California • Orange, California + 35 more